Abstract
The treatment of common multi-factorial, system-wide diseases using multi-component therapeutics, such as herbal medicines, can be regarded as a “system to system” therapeutic approach. The pharmacokinetics (PK) of multi-component therapeutics is a great technical challenge, which has led to significant limitations in understanding the efficacies and toxicities of combination drugs and herbal medicines. Metabolomics has clearly demonstrated its value in elucidating the interaction of the biological systems genome with its environments, and recently been used in the PK analysis of drugs, xenobiotics and several nutrients. The metabolomics strategy can also be used in pharmacokinetic study of plant derived agents to demonstrate their biological fates, thereby linking the plant metabolome to human/ animal metabolome, and bridging the gap between multi-component agents and molecular pharmacology. This paper reviews the current progress of metabolomics based PK studies, presents the potentials and challenges of such a strategy for herbal medicines, as well as looks into the future of the role of metabolomics in the relationship between PK, PD and TOX of herbal medicines.
Keywords: Metabolomics, herbal medicine, pharmacokinetics, drug metabolism
Current Drug Metabolism
Title: An Integrated Metabolomics and Pharmacokinetics Strategy for Multi-Component Drugs Evaluation
Volume: 11 Issue: 1
Author(s): Ke Lan and Wei Jia
Affiliation:
Keywords: Metabolomics, herbal medicine, pharmacokinetics, drug metabolism
Abstract: The treatment of common multi-factorial, system-wide diseases using multi-component therapeutics, such as herbal medicines, can be regarded as a “system to system” therapeutic approach. The pharmacokinetics (PK) of multi-component therapeutics is a great technical challenge, which has led to significant limitations in understanding the efficacies and toxicities of combination drugs and herbal medicines. Metabolomics has clearly demonstrated its value in elucidating the interaction of the biological systems genome with its environments, and recently been used in the PK analysis of drugs, xenobiotics and several nutrients. The metabolomics strategy can also be used in pharmacokinetic study of plant derived agents to demonstrate their biological fates, thereby linking the plant metabolome to human/ animal metabolome, and bridging the gap between multi-component agents and molecular pharmacology. This paper reviews the current progress of metabolomics based PK studies, presents the potentials and challenges of such a strategy for herbal medicines, as well as looks into the future of the role of metabolomics in the relationship between PK, PD and TOX of herbal medicines.
Export Options
About this article
Cite this article as:
Lan Ke and Jia Wei, An Integrated Metabolomics and Pharmacokinetics Strategy for Multi-Component Drugs Evaluation, Current Drug Metabolism 2010; 11 (1) . https://dx.doi.org/10.2174/138920010791110926
DOI https://dx.doi.org/10.2174/138920010791110926 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Colorectal Cancer-Associated Fibroblasts are Genotypically Distinct
Current Cancer Therapy Reviews Dietary Fatty Acids in Metabolic Syndrome, Diabetes and Cardiovascular Diseases
Current Diabetes Reviews Evaluation of Non-Coding RNAs as Potential Targets in Head and Neck Squamous Cell Carcinoma Cancer Stem Cells
Current Drug Targets Polymeric Nanotubes and Nanorods for Biomedical Applications
Current Nanoscience The Immunological Side-Effects of Sedative Agents in the Intensive Care Unit
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Host Pharmacogenetics in the Treatment of HIV and Cancer
Current Drug Safety Molecular Mechanisms of Inflammation. Anti-Inflammatory Benefits of Virgin Olive Oil and the Phenolic Compound Oleocanthal
Current Pharmaceutical Design Tumor Dormancy and the Angiogenic Switch: Possible Implications of Bone Marrow- Derived Cells
Current Pharmaceutical Design Microsatellite Instability (MSI) as Genomic Marker in Endometrial Cancer: Toward Scientific Evidences
Mini-Reviews in Medicinal Chemistry The Roles of Chromatin Remodeling Proteins in Cancer
Current Protein & Peptide Science Emerging Roles for Modulation of microRNA Signatures in Cancer Chemoprevention
Current Cancer Drug Targets Innovation in Contrast Agents for Magnetic Resonance Imaging
Current Medical Imaging Current Dendrimer Applications in Cancer Diagnosis and Therapy
Current Topics in Medicinal Chemistry Editorial (Thematic Issue: Development of Biomarkers in Tumors of Digestive System Part II)
Anti-Cancer Agents in Medicinal Chemistry Oleuropein Mediated Targeting of Signaling Network in Cancer
Current Topics in Medicinal Chemistry Cellular FLICE-Like Inhibitory Protein (C-FLIP): A Novel Target for Cancer Therapy
Current Cancer Drug Targets The Cross-over of Anticancer Agents with Osteoclast Activities
Current Cancer Therapy Reviews RNAi Screening Identifies TAK1 as a Potential Target for the Enhanced Efficacy of Topoisomerase Inhibitors
Current Cancer Drug Targets Glucose-6-phosphate Dehydrogenase: a Biomarker and Potential Therapeutic Target for Cancer
Anti-Cancer Agents in Medicinal Chemistry Preclinical and Clinical Studies of Novel Breast Cancer Drugs Targeting Molecules Involved in Protein Kinase C Signaling, the Putative Metastasis-Suppressor Gene Cap43 and the Y-box Binding Protein-1
Current Medicinal Chemistry